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Olatunji O Adetokunboh1,2*, Anel Schoonees1 and Charles S Wiysonge1,2Abstract
Background: Abacavir is one of the recommended nucleoside reverse transcriptase inhibitors (NRTIs) for the
treatment of HIV infections among children and adolescents. However, there are concerns that the antiviral efficacy
of abacavir might be low when compared to other NRTIs especially among children. There are also concerns that
abacavir use may lead to serious adverse events such as hypersensitivity reactions and has potential predisposition
to developing cardiovascular diseases.
Methods: We plan to do a systematic review to evaluate the antiviral efficacy and safety of abacavir-containing
combination antiretroviral therapy as first-line treatment of HIV-infected children aged between 3 months and 18 years,
compared with other NRTIs. We will search Scopus, Cochrane Central Register of Controlled Trials, MEDLINE, and Web
of Science databases for eligible studies regardless of language or publication status. We will check the reference lists
of included studies, search relevant conference proceedings, email the authors of included studies and also look for
unpublished and ongoing trials in prospective clinical trial registries. Two authors will independently screen search
outputs, select studies, extract data and assess the risk of bias in included studies. All disagreements will be resolved by
discussion and consensus. Where data allow, we will conduct meta-analysis for similar types of participants, study
designs, interventions, and outcome measures. If the results are statistically homogeneous, we will use the fixed-effect
model; otherwise, we will use the random-effects model and explore the reasons for heterogeneity using subgroup
analyses. Heterogeneity will be assessed with the Chi-squared test and quantified with the I-squared statistic.
Discussion: The findings will be useful to policy makers and programme managers to inform treatment and
management of HIV in children and adolescents and to point out research gaps for future research.
Trial registration: This review is registered with PROSPERO, registration number CRD42014009157.
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The acquired immunodeficiency syndrome (AIDS) re-
mains a major global concern with estimated 3.3 million
under 15 years of age children and adolescents currently
living with the human immunodeficiency virus (HIV)
and about 2 million needing antiretroviral therapy [1]. In* Correspondence: adetok_sic@yahoo.com
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article, unless otherwise stated.order to effectively manage HIV infection and AIDS, it
is recommended that antiretroviral treatment regimens
should consist of a three-drug combination consisting of
two nucleoside reverse transcriptase inhibitors (NRTIs)
with either one protease inhibitor (PI) or a non-nucleoside
reverse transcriptase inhibitor (NNRTI) depending on the
age of the patient and other co-morbidities [2]. In the treat-
ment of children infected by HIV, abacavir is one of the
recommended NRTIs in children younger than 10 years of
age [2]. Abacavir, formerly known as 1592U89, is a carbo-
cyclic 2′-deoxyguanosine nucleoside analogue with its mainentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Adetokunboh et al. Systematic Reviews 2014, 3:87 Page 2 of 6
http://www.systematicreviewsjournal.com/content/3/1/87activity being against HIV type 1 (HIV-1). It is phosphory-
lated to its active metabolite, carbovir triphosphate, which
inhibits the HIV-1 reverse transcriptase competitively and
terminates deoxyribonucleic acid (DNA) synthesis. This
prevents HIV from replicating, thereby lowering the
amount of HIV in the body system [3].
The two NRTIs in a three-drug antiretroviral regimen
are referred to as the NRTI backbones of the regimen.
As shown in Table 1, the World Health Organization
(WHO) recommends abacavir and either lamivudine or
zidovudine as the NRTI backbones for children younger
than 3 years of age. There is a strong recommendation for
the use of these two NRTI backbones as fixed-dose combi-
nations in this paediatric age group; however, this recom-
mendation was done with a low certainty of evidence [2].
In 3- to 10-year-old children and adolescents weighing less
than 35 kg, abacavir-lamivudine is the NRTI backbone
commonly used. Again, this regimen has strong recom-
mendation for use but low certainty of evidence [2].
The WHO guidelines suggest that stavudine, a NRTI,
be replaced by abacavir because of toxicity concerns.
However, abacavir has adverse effect concerns of its own
[4]. Abacavir is associated with a systemic illness known
as abacavir hypersensitivity reaction that can result in
death if the drug is not discontinued in affected patients.
This hypersensitivity may present with fever, maculopapu-
lar rash and other constitutional symptoms such as fa-
tigue, malaise and myalgia. Gastrointestinal adverse effects
such as vomiting, diarrhoea and abdominal pain may also
occur. Occasionally, there are also some prominent re-
spiratory symptoms, such as tachypnea and cough [5,6].
Hypersensitivity reactions due to abacavir have been re-
ported in both paediatric and adult populations with the
incidence in randomised controlled trials ranging from 0%
to 14% [6]. HIV-infected individuals of African descent
seems to have reduced risk of abacavir hypersensitivity [7],
and the wide variation in reported adverse event incidenceTable 1 Summary of WHO recommended first-line antiretrovi
Children 3 years to less than 10 years an
Preferred ABCa + 3TC + EFV
Alternatives ABC + 3TC + NVP
AZT + 3TC + EFV
AZT + 3TC + NVP
TDF + 3TC (or FTC) + EFV
TDF + 3TC (or FTC) + NVP
Special circumstancesc d4Tb + 3TC + EFV
d4Tb + 3TC + NVP
aThese recommendations apply to children and adolescents who are initiating first-
toxicity to AZT is suspected or confirmed and access to ABC or TDF is lacking.
cSpecial circumstances may include situations where preferred or alternative regime
anticipated drug-drug interactions, drug procurement and supply management issu
3TC lamivudine, ABC abacavir, AZT zidovudine, d4T stavudine, EFV efavirenz, FTC em
Health Organization.with abacavir use makes it necessary to do a systematic
review, especially in children. In addition, some cohort
studies in South Africa have shown poor virological
responses to abacavir-based regimens when compared to
stavudine in children. These studies queried the clinical
effectiveness of abacavir when compared to the other
NRTIs as well as the justification for making it a first-line
drug in the treatment of HIV in children [8,9]. A further
investigation on the drug is thus needed.
Some research studies suggested that abacavir
increases the risk of cardiovascular events, especially
myocardial infarction [10,11]. However, meta-analyses
of randomised controlled trials in adults have not sup-
ported the postulation that abacavir-containing anti-
retroviral regimens carry a greater risk of cardiovascular
events relative to abacavir-sparing regimens [12,13].
Similarly, various studies evaluating changes in inflam-
matory and coagulopathic biomarkers upon commence-
ment of abacavir-containing regimens have produced
conflicting findings [14,15]. These randomised con-
trolled trials were carried out mainly on adults due to
the belief that children have lower incidence of some of
these important adverse effects of abacavir [16]. A
meta-analysis of HIV-infected adults switching to
abacavir-containing regimens shows rather weak
evidence of lower incidence of adverse events, with
higher incidence of virological failure in the NRTI
groups when compared to the controls [17].
Despite concerns that the confidence in the currently
available evidence on the antiviral efficacy of abacavir
might be low, coupled with serious adverse events such
as hypersensitivity reactions and a potential predispos-
ition to developing cardiovascular diseases, the WHO
has recommended abacavir as one of the preferred NRTI
backbones in the paediatric population [4]. However, we
are not aware of any systematic review of the safety of
abacavir-containing regimens in HIV-infected children.ral regimens for children and adolescents [2]
d adolescents <35 kg Adolescents (10 to 19 years) ≥35 kg
TDF + 3TC (or FTC) + EFVa
AZT + 3TC + EFV
AZT + 3TC + NVP
TDF + 3TC (or FTC) + NVP
ABC + 3TC + EFV
ABC + 3TC + NVP
line antiretroviral therapy; bd4T use should be restricted to situations in which
ns may not be available or suitable because of significant toxicities,
es, or for other reasons.
tricitabine, LPV/r lopinavir/ritonavir, NVP nevirapine, TDF tenofovir, WHO World
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The primary objective is to assess the antiviral efficacy
of abacavir-containing combination antiretroviral regi-
mens in comparison with combination antiretroviral reg-
imens containing other NRTIs as first-line therapy for
HIV-infected children and adolescents.
The secondary objective is to assess the safety of
abacavir-containing combination antiretroviral regimens
in HIV-infected children and adolescents.
Methods
This review protocol has been published in the PROSPERO
International Prospective Register of systematic reviews
(http://www.crd.york.ac.uk/PROSPERO), registration num-
ber CRD42014009157 [18]. The PROSPERO database
provides a comprehensive listing of systematic reviews
registered at the start to help prevent unintended du-
plication and allows comparison of published review
methods with what was intended in the protocol.
Criteria for considering studies for this review
Types of studies
Experimental (randomised controlled trials and non-
randomised controlled trials) and prospective observational
studies with control groups will be eligible for inclusion in
this systematic review. Non-randomised controlled trials
refer to studies that allocated participants to interventions
and controls using alternation between groups, by the use of
birth dates or weekdays or by other non-random methods.
Types of participants
HIV-infected individuals between 3 months and 18 years
of age.
Types of interventions
Experimental group: abacavir-containing combination
antiretroviral regimens as first-line therapy.
Control group: combination antiretroviral regimens
containing zidovudine or tenofovir or stavudine in the
NRTI backbone as first-line therapy.





1. Adverse events requiring treatment interruption
or switching
2. CD4 cell count
3. Hypersensitivity reaction (fever, nausea, respiratory
discomfort, rash and diarrhoea)4. Death (all cause)
5. Myocardial infarction and other cardiovascular events
Search methods for identification of studies
With the support of a librarian at the University of
Stellenbosch's Faculty of Medicine and Health Sciences,
we will do an exhaustive search to identify all the relevant
studies regardless of language or publication status.
Databases
We will search the following electronic databases:
MEDLINE via PubMed, Cochrane Central Register of
Controlled Trials (CENTRAL), Scopus, and ISI Web of
Science (Science Citation Index). Both text words and
medical subject heading (MeSH) terms, for example
abacavir, antiretroviral, HIV, acquired immunodefi-
ciency syndrome, child, paediatric, adolescent and ran-
domised controlled trial will be used in the search
strings. We will use these terms in different combina-
tions with the adaptation of the literature search strat-
egy to suit each database (see Additional file 1 for the
proposed search strategy adapted from Shey et al. [19]).
Conference proceedings
We will search the proceedings of the following confer-
ences for potentially eligible studies: The European AIDS
Clinical Society (EACS) conferences, International AIDS
conferences, Conference on Retroviruses and Opportun-
istic Infections (CROI) and International AIDS Society
conference on HIV Pathogenesis and Treatment (IAS).
Other resources
We will search for unpublished and ongoing studies in pro-
spective clinical trial registries such as ClinicalTrials.gov
and WHO International Clinical Trials Registry Platform.
In addition, we will contact authors of studies included in
this review to find out if they know of any other relevant
studies in the field. Lastly, we will search the reference lists
of included studies and relevant systematic reviews.
Data collection and analysis
The data collection and analysis for this review will be
based on standard Cochrane Collaboration methods [20].
Selection of studies
Two members of the research team will independently
screen the titles and abstracts identified by the literature
searches and identify all potentially eligible studies. We
will then obtain the full text articles for these and review
them independently. We will resolve all disagreements
by discussion and consensus within the author team.
Reasons for excluding studies previously identified as
potentially eligible will be recorded in the table of
excluded studies.
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Two members of the team will independently extract
data using a pre-piloted data extraction form. The fol-
lowing data will be extracted:
a. Details of the study (setting, study design, date and
time period)
b. Details of participants (age, gender, co-morbidities,
relevant baseline characteristics)
c. Details of the treatment and control interventions,
including dose and exact regimens
d. Number of participants randomised per group and
number of withdrawals per group with reasons
e. Numerical results for each of our pre-specified
outcomes
f. Conflicts of interest declarations and funding sources
In case of missing or unclear information in any of the
included studies, we will try to get further information
or clarity from the trial authors via email. The two au-
thors will compare extracted data for each study and re-
solve any differences by discussion and consensus, with
the third author arbitrating if necessary. One author will
enter the final data into the latest version of the
Cochrane Collaboration Review Manager, currently ver-
sion 5.2 (RevMan 5.2) [21], and the second author will
cross-check the data for data entry errors and rectify
where needed.
Assessment of risk of bias in included studies
Two authors will independently assess the risk of bias in
each included experimental study using the domain-based
tool as described in the Cochrane Handbook for Syste-
matic Reviews of Interventions 5.1.0 [20]. The following
domains will be assessed: random sequence generation,
allocation concealment, blinding of participants and
personnel, blinding of outcome assessors, incomplete out-
come data, selective reporting and other biases (baseline
imbalances, industry involvement and conflicts of inter-
est). Judgements will be made as low risk of bias, unclear
risk of bias or high risk of bias according to the criteria in
the Cochrane Handbook [20]. Two authors will compare
the assessments and resolve differences by discussion and
consensus. In case of failure to resolve the difference, a
third author will be called upon to arbitrate. RevMan 5.2
will be used to display the results of the risk of bias assess-
ment per study and overall per domain [20].
Regarding included prospective observational studies,
the two authors will also independently evaluate the
methodological quality by using the Newcastle-Ottawa
Quality Assessment Scale [22]. Emphasis will be placed
on the method of selection of the sample, the type,
length and completeness of follow-up and objectivity of
outcome assessment.Measures of treatment effect Dichotomous data will
be expressed as risk ratios (RR) and continuous data as
mean differences (MD).
Dealing with missing data Where information on re-
sults is unclear or missing, we will get in touch with trial
authors via email. Where appropriate, data will be ana-
lysed with both the intention-to-treat (ITT) and avail-
able case principles.
Assessment of heterogeneity Data will only be pooled
from studies judged to be largely homogenous in trial par-
ticipants, interventions and various outcomes. We will
visually inspect the forest plots to check for overlapping of
intervention effects across the included studies. Following
the visual inspection, we will conduct the Chi-squared test
of homogeneity to formally test for heterogeneity of study
effects, defining significance at α = 10%. In addition, we
will use the I-squared statistic to quantify heterogeneity of
effects among the trials, where an I-square value above
50% is seen as substantial heterogeneity [20].
Quality of evidence The quality of the evidence (also
referred to as certainty of the evidence, confidence in
the estimate or strength of the evidence) is an assess-
ment suggesting the confidence we can place in the find-
ings. We will assess the quality of our review's evidence by
using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) tool and incor-
porate the GRADE profiles in ‘summary of findings’
tables. The GRADE approach results in judging the
evidence per outcome as high, moderate, low or very
low [23,24]. Reasons for downgrading or upgrading
evidence, for randomised controlled trails and observa-
tional studies respectively, will be provided.
Assessment of reporting biases In the case of at least
ten studies included in a meta-analysis, we will assess
the likelihood of publication bias for the outcome(s)
using funnel plot techniques [20].
Data synthesis Data analysis will be conducted using
the latest RevMan software (currently version 5.2) [21].
Where included studies are found to be clinically and
statistically homogeneous, they will be pooled in a meta-
analysis. Effect sizes will be reported alongside 95%
confidence intervals.
Meta-analysis will be done using the fixed-effect model
when the Chi-squared test yields P > 0.1 or when the I-
squared value is below 50%; otherwise, the random-
effects model will be used. When the I-squared value is
greater than 75%, indicating considerable heterogeneity
[20], results of individual studies will not be pooled. If
we are unable to conduct meta-analyses, a narrative
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results will be provided in a table.
Subgroup analysis and investigation of heterogeneity
We propose to conduct subgroup analyses, with sub-
groups defined by type of antiretroviral agents in the
intervention or control groups, age group (infants,
children and adolescents) and study setting (low-income,
middle-income and high-income countries). These ana-
lyses will only be performed for the primary outcomes.
Sensitivity analysis Sensitivity analyses will be con-
ducted to assess the effects of risk of bias and different
statistical methods employed in the meta-analyses for the
primary outcomes. Regarding risk of bias, our focus will
be on allocation concealment (with and without studies
with high or unclear risk), blinded outcome assessment
(with and without studies with high or unclear risk) and
losses to follow-up (with and without studies that had
≥30% attrition or differential attrition). Regarding the
potential effects of different statistical methods, we will
compare results of ITT and available case analysis.
Presenting and reporting of results We will display
the study selection process by means of a flow diagram and
provide reasons for exclusion of studies. We will follow the
PRISMA guidelines for reporting of systematic reviews
[25]. The search strings will be published as supplementary
documents. We will also display the risk of bias tables,
forest plots and summary of findings table(s) as appropriate.
Discussion
To the best of our knowledge, there are no published sys-
tematic reviews that have specifically assessed the antiviral
efficacy and safety of abacavir-containing combination anti-
retroviral regimens in the paediatric population. There are
however systematic reviews on abacavir-containing com-
bination antiretroviral regimens in adults [12,13,16,19]. The
study team plans to address this gap with the proposed
systematic review outlined in this protocol. The summary
of the available scientific evidence would shed light on the
antiviral performance of abacavir as first-line treatment of
HIV-infected children and adolescents.
This study may also inform decision makers about
abacavir's risk of adverse events, including cardiovascu-
lar events. Understanding the virological performance of
abacavir in HIV-infected children in comparison to the
less preferred antiretroviral agents is crucial in order to
prevent suboptimal long-term outcomes. We also hope
to identify gaps in the research that may form the basis
for future studies of various aspects of abacavir in the
paediatric population. The findings of this review are to
be used by decision makers to inform treatment policy
and paediatric HIV management practices.Additional file
Additional file 1: Medline search strategy using PubMed.
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